Connective Tissue Diseases
4
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
150%
Monoclonal Antibody
150%
+ 4 programs with unclassified modality
Competitive Landscape
5 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
2 programs1
1
SirolimusPhase 41 trial
TelitaciceptPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UNION therapeuticsSirolimus
UNION therapeuticsTelitacicept
BiocorpCAR-T
Boehringer IngelheimPulmonary function test
Clinical Trials (4)
Total enrollment: 436 patients across 4 trials
Study of Sirolimus in CTD-TP in China
Start: Sep 2017Est. completion: Sep 201920 patients
Phase 4Unknown
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Start: Dec 2023Est. completion: Dec 2025296 patients
Phase 2Recruiting
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Start: Aug 2025Est. completion: Mar 20260
N/AWithdrawn
Connective Tissue Diseases and Lung Manifestations
Start: Dec 2019Est. completion: Oct 2034120 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 436 patients
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.